Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Weightloss in Menopause

Susan Brian

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

GLP-1 Agonists and GI: All We Need to Know

UT Health San Antonio School of Medicine

P. Jirapinyo

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Heart Failure in Women: 2025 Update

Scripps Health

M. Kittleson

Tirzepatide Updates

Diana Isaacs

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

Tirzepatide for Type 2 Diabetes

Diana Isaacs